Production (Stage)
InnoCan Pharma Corporation
INNPF
$0.114
-$0.007-5.79%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 44.34% | -37.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 44.34% | -37.37% | |||
| Cost of Revenue | -31.35% | 17.40% | |||
| Gross Profit | 61.37% | -43.32% | |||
| SG&A Expenses | 28.79% | -29.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.62% | -23.60% | |||
| Operating Income | 153.21% | -361.08% | |||
| Income Before Tax | 1,000.00% | -99.57% | |||
| Income Tax Expenses | 413.73% | -87.80% | |||
| Earnings from Continuing Operations | -377.08% | -116.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -434.85% | 88.50% | |||
| Net Income | -410.53% | 60.69% | |||
| EBIT | 153.21% | -361.08% | |||
| EBITDA | 154.65% | -352.91% | |||
| EPS Basic | -400.00% | 60.00% | |||
| Normalized Basic EPS | -450.00% | 60.00% | |||
| EPS Diluted | -400.00% | 60.00% | |||
| Normalized Diluted EPS | -450.00% | 60.00% | |||
| Average Basic Shares Outstanding | 1.15% | 1.91% | |||
| Average Diluted Shares Outstanding | 1.15% | 1.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||